Goodwin @ JP Morgan

GoodwinSpeaks: Goodwin @ JP Morgan Seminars

The St. Regis San Francisco
125 3rd Street
San Francisco, CA 94103

Topic 1:

Hong Kong – An Emerging Capital Markets Hub for Innovative Biotech Companies (in partnership with HKEX and KPMG)

This is a kick off panel discussion with HKEX and KPMG hosted by Goodwin as a part of larger roadshow around the changes to the listing standards to allow clinical stage biotechs to list + short state of the market. The next two sessions will be in NYC on January 15, 2019 and in Boston January 17, 2019.

8:00 am – 8:30 am – Registration + Breakfast
8:30 am – 9:00 am – Keynote Address - Charles Lee, CEO of The Hong Kong Stock Exchange
9:00 am – 10:00 am – Panel Discussion 

• Andrew Weir – Sr. Partner, Hong Kong/Vice Chairman, KPMG China
• Irene Chu – Partner, Head of New Economy and Life Sciences Hong Kong, KPMG China
• Miron Lila – Director, Asia Healthcare Investment Banking, Citigroup
• Michael Chan – Senior Vice President, Issuer Services, Market Development, HKEX
• Edwin O’Connor – Partner, Goodwin
• Bosco Yiu – Partner, Goodwin

Topic 2:

Launching a Biosimilar In the U.S.:  Practical Considerations for Foreign Developers 

11:30 – 12:00 pm – Registration &  Lunch
12:00 – 1:00 pm – Panel Discussion

Topic 3:

Digital Medicine: Lessons from Biopharma  

1:30 pm – 2:00 pm – Registration + Refreshments
2:00 – 3:00 pm – Panel Discussion

• Eddie Martucci – CEO, Akili Interactive
• David O’Reilly – Chief Platform Officer, Proteus Digital Healh
• Jon Civitarese – Managing Director, Leerink Partners LLC
• Arthur McGivern – Partner, Goodwin
• Roger Cohen – Partner, Goodwin

Topic 4:

 Don’t Let Milestones Become Millstones: How to Turn Structured Consideration to Your Advantage in Biotech M&A Transactions

4:00 – 4:30 pm – Registration
4:30 – 5:30 pm – Panel Discussion
5:30 – 6:30 pm – Cocktails & Appetizers

• Kees Been – CEO, Lysosomal
• Maarten de Jong – Moelis
• Graham Defries – Partner, Goodwin

Goodwin knows that succeeding in the life sciences industry is as much about strategy and execution as it is about research and development. In this highly competitive business, you need more than the best and brightest ideas - you need a legal and strategic partner that understands the challenges of securing funding, safeguarding intellectual property, establishing partnerships, bringing new products to market, opening up new revenue streams, and protecting existing products line.

Goodwin can help. We know the market, the players and the science. With a full service team of highly experienced lawyers resident in key life sciences hubs, Goodwin helps clients find the strategic paths that foster growth and minimize risk across all phases of the corporate life cycle.

Click here to learn more about Gooodwin's Life Sciences practice.

Goodwin's Big Molecule Watch blog posts updates and analyses on regulatory issues, litigation, legislation, and other news in the ever-developing world of biosimilars. The editors of this blog have collectively been watching and engaging with the world of biosimilars (“big molecules”) since before the inception of the biosimilar industry in the U.S., and we’re excited to share the observations of our active watch on this new forum. Read the Big Molecule Watch Blog >>